CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 164 enrolled
Drug / intervention
CervarixTM (GSK580299)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01418937
NCT01418937Phase 3Completed
CompareCT.gov

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study

GlaxoSmithKline·interventional·Posted Aug 17, 2011·Updated Jul 12, 2018

In Brief

A Phase 3 clinical trial evaluating CervarixTM (GSK580299) for Infections, Papillomavirus. Completed, enrolled 164 participants across 5 sites.

Detailed Summary

This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741) study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Papillomavirus
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2011
Enrollment StartMay 29, 2012
Primary CompletionJan 9, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.9 years ago

Interventions

CervarixTM (GSK580299)biological

Three intramuscular injections